Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant

被引:5
|
作者
Hu, Songhua [1 ]
Xiong, Chenfeng [2 ]
Zhao, Yingrui [3 ]
Yuan, Xin [2 ]
Wang, Xuqiu [2 ]
机构
[1] Univ Maryland, Dept Civil & Environm Engn, College Pk, MD 20742 USA
[2] Villanova Univ, Dept Civil & Environm Engn, Villanova, PA 19085 USA
[3] Univ Maryland, Dept Geog Sci, College Pk, MD 20742 USA
基金
美国国家卫生研究院;
关键词
COVID-19; Vaccination; Human mobility; Omicron; Disparity; Mediation analysis; DATA REVEAL;
D O I
10.1016/j.vaccine.2023.05.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The B.1.1.529 (Omicron) variant surge has raised concerns about the effectiveness of vaccines and the impact of imprudent reopening. Leveraging over two years of county-level COVID-19 data in the US, this study aims to investigate relationships among vaccination, human mobility, and COVID-19 health out-comes (assessed via case rate and case-fatality rate), controlling for socioeconomic, demographic, racial/ethnic, and partisan factors. A set of cross-sectional models was first fitted to empirically compare disparities in COVID-19 health outcomes before and during the Omicron surge. Then, time-varying medi-ation analyses were employed to delineate how the effects of vaccine and mobility on COVID-19 health outcomes vary over time. Results showed that vaccine effectiveness against case rate lost significance during the Omicron surge, while its effectiveness against case-fatality rate remained significant through-out the pandemic. We also documented salient structural inequalities in COVID-19-related outcomes, with disadvantaged populations consistently bearing a larger brunt of case and death tolls, regardless of high vaccination rates. Last, findings revealed that mobility presented a significantly positive relation-ship with case rates during each wave of variant outbreak. Mobility substantially mediated the direct effect from vaccination to case rate, leading to a 10.276 % (95 % CI: 6.257, 14.294) decrease in vaccine effectiveness on average. Altogether, our study implies that sole reliance on vaccination to halt COVID-19 needs to be re-examined. Well-resourced and coordinated efforts to enhance vaccine effectiveness, mitigate health disparity and selectively loosen non-pharmaceutical interventions are essential to bring-ing the pandemic to an end.& COPY; 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5097 / 5112
页数:16
相关论文
共 50 条
  • [21] The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England
    Paton, Robert S.
    Overton, Christopher E.
    Ward, Thomas
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (652)
  • [22] Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates
    Mohapatra, Ranjan K.
    Tiwari, Ruchi
    Sarangi, Ashish K.
    Islam, Md. Rabiul
    Chakraborty, Chiranjib
    Dhama, Kuldeep
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (06) : 2336 - 2342
  • [23] Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health
    Islam, Md Rabiul
    Nasreen, Waheeda
    Anjum, Ramisa
    Shahriar, Mohammad
    Roy, Arpita
    Dhama, Kuldeep
    Bhuiyan, Mohiuddin Ahmed
    CLINICAL PATHOLOGY, 2022, 15
  • [24] A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
    Manjunath, R.
    Gaonkar, Santosh L.
    Saleh, Ebraheem Abdu Musad
    Husain, Kakul
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (09)
  • [25] Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved
    Jergovic, Mladen
    Coplen, Christopher P.
    Uhrlaub, Jennifer L.
    Beitel, Shawn C.
    Burgess, Jefferey L.
    Lutrick, Karen
    Ellingson, Katherine D.
    Watanabe, Makiko
    Nikolich-Zugich, Janko
    JOURNAL OF IMMUNOLOGY, 2022, 208 (11): : 2461 - 2465
  • [26] Omicron (B.1.1.529): constellation of unusual mutations in SARS-CoV-2
    Kashyap, Abhishek
    Banerjee, Indrajit
    AFRICAN HEALTH SCIENCES, 2023, 23 (02) : 1 - 2
  • [27] The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?
    Jaffar A. Al-Tawfiq
    Van-Thuan Hoang
    Nhat Le Bui
    Dinh-Toi Chu
    Ziad A. Memish
    Journal of Epidemiology and Global Health, 2022, 12 : 143 - 146
  • [28] Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
    Shuai, Huiping
    Chan, Jasper Fuk-Woo
    Hu, Bingjie
    Chai, Yue
    Yuen, Terrence Tsz-Tai
    Yin, Feifei
    Huang, Xiner
    Yoon, Chaemin
    Jing-Chu Hu
    Liu, Huan
    Shi, Jialu
    Liu, Yuanchen
    Zhu, Tianrenzheng
    Zhang, Jinjin
    Hou, Yuxin
    Wang, Yixin
    Lu, Lu
    Jian-Piao Cai
    Zhang, Anna Jinxia
    Zhou, Jie
    Yuan, Shuofeng
    Brindley, Melinda A.
    Bao-Zhong Zhang
    Jian-Dong Huang
    To, Kelvin Kai-Wang
    Kwok-Yung Yuen
    Chu, Hin
    NATURE, 2022, 603 (7902) : 693 - +
  • [29] Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
    Huiping Shuai
    Jasper Fuk-Woo Chan
    Bingjie Hu
    Yue Chai
    Terrence Tsz-Tai Yuen
    Feifei Yin
    Xiner Huang
    Chaemin Yoon
    Jing-Chu Hu
    Huan Liu
    Jialu Shi
    Yuanchen Liu
    Tianrenzheng Zhu
    Jinjin Zhang
    Yuxin Hou
    Yixin Wang
    Lu Lu
    Jian-Piao Cai
    Anna Jinxia Zhang
    Jie Zhou
    Shuofeng Yuan
    Melinda A. Brindley
    Bao-Zhong Zhang
    Jian-Dong Huang
    Kelvin Kai-Wang To
    Kwok-Yung Yuen
    Hin Chu
    Nature, 2022, 603 : 693 - 699
  • [30] Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529)
    Yonekawa, Akiko
    Shimono, Nobuyuki
    BIOLOGY-BASEL, 2022, 11 (03):